Page |1
BSN HESI 315 Pharmacology & Exit Exam – Complete Test (2026) Actual
Questions with Answers and Rationale 100% Verified Correct
Instructions: Detailed rationales are provided to reinforce advanced
pharmacology concepts.
Domain 1: Pharmacokinetics & Pharmacodynamics (Absorption, Distribution,
Metabolism, Excretion)
1. A patient with renal impairment is prescribed a drug that is primarily
eliminated unchanged by the kidneys. Which pharmacokinetic parameter will be
most significantly altered?
A) Volume of distribution (Vd)
B) Bioavailability
C) Half-life (t½)
D) Peak plasma concentration (Cmax)
Answer: C
Rationale: Half-life (t½) is directly affected by clearance (CL) and volume of
distribution (Vd): t½ = (0.693 × Vd) / CL. If renal clearance is reduced, the drug's
half-life will increase, leading to accumulation and potential toxicity.
2. A patient is taking a drug with a half-life of 6 hours. Approximately how long
will it take to reach steady-state (plateau) concentration?
A) 6 hours
B) 12 hours
C) 24 hours
D) 30 hours (5 half-lives)
Answer: D
Rationale: It takes approximately 4–5 half-lives to reach steady-state. 5 × 6 hours =
30 hours. At steady-state, the rate of drug administration equals the rate of
elimination.
, Page |2
3. The CYP450 enzyme system is primarily located in which organ and is
responsible for:
A) The liver; Phase I metabolism (oxidation, reduction, hydrolysis)
B) The kidneys; filtration
C) The lungs; gas exchange
D) The intestines; absorption
Answer: A
Rationale: The Cytochrome P450 (CYP) enzyme system is predominantly located in
the liver's endoplasmic reticulum. It catalyzes Phase I reactions, which introduce a
reactive functional group onto the drug molecule.
4. A patient on warfarin is started on a drug that strongly inhibits CYP2C9. What
is the expected clinical outcome?
A) Warfarin will be metabolized faster, leading to reduced anticoagulation.
B) Warfarin will be metabolized slower, leading to increased INR and bleeding risk.
C) No change in warfarin levels.
D) Warfarin will be excreted faster.
Answer: B
Rationale: Warfarin is metabolized by CYP2C9. If this enzyme is inhibited, warfarin
metabolism decreases, leading to higher plasma concentrations. This increases the
patient's INR and significantly raises the risk of major bleeding.
5. A drug has a volume of distribution (Vd) of 10,000 L. This indicates that the
drug is:
A) Highly bound to plasma proteins
B) Highly tissue-bound and widely distributed into extravascular tissues
C) Primarily confined to the vascular space
D) Excreted rapidly
Answer: B
Rationale: Volume of distribution (Vd) is a theoretical volume that relates the
amount of drug in the body to the plasma concentration. A very high Vd (like
, Page |3
10,000 L) indicates that the drug is extensively distributed into tissues (e.g., fat,
muscle, organs).
6. The "first-pass effect" refers to:
A) The metabolism of a drug in the liver before it reaches systemic circulation,
which significantly reduces the bioavailability of oral medications
B) The first dose of a drug given to a patient
C) The absorption of a drug in the stomach
D) The excretion of a drug in the urine
Answer: A
Rationale: The first-pass effect occurs when an orally administered drug is
absorbed from the GI tract and passes through the portal vein into the liver before
it can enter the systemic circulation. The liver may metabolize a significant portion
of the drug.
Domain 2: Autonomic Nervous System Pharmacology (Adrenergic & Cholinergic)
7. Which neurotransmitter is released at the postganglionic terminals of the
parasympathetic nervous system?
A) Norepinephrine
B) Dopamine
C) Acetylcholine
D) Epinephrine
Answer: C
Rationale: In the parasympathetic nervous system, both the preganglionic and
postganglionic neurons release acetylcholine (ACh).
8. A patient is given a drug that stimulates the sympathetic nervous system
(sympathomimetic). Which receptor type is primarily responsible for causing
bronchodilation?
A) Alpha-1 (α₁)
B) Alpha-2 (α₂)
BSN HESI 315 Pharmacology & Exit Exam – Complete Test (2026) Actual
Questions with Answers and Rationale 100% Verified Correct
Instructions: Detailed rationales are provided to reinforce advanced
pharmacology concepts.
Domain 1: Pharmacokinetics & Pharmacodynamics (Absorption, Distribution,
Metabolism, Excretion)
1. A patient with renal impairment is prescribed a drug that is primarily
eliminated unchanged by the kidneys. Which pharmacokinetic parameter will be
most significantly altered?
A) Volume of distribution (Vd)
B) Bioavailability
C) Half-life (t½)
D) Peak plasma concentration (Cmax)
Answer: C
Rationale: Half-life (t½) is directly affected by clearance (CL) and volume of
distribution (Vd): t½ = (0.693 × Vd) / CL. If renal clearance is reduced, the drug's
half-life will increase, leading to accumulation and potential toxicity.
2. A patient is taking a drug with a half-life of 6 hours. Approximately how long
will it take to reach steady-state (plateau) concentration?
A) 6 hours
B) 12 hours
C) 24 hours
D) 30 hours (5 half-lives)
Answer: D
Rationale: It takes approximately 4–5 half-lives to reach steady-state. 5 × 6 hours =
30 hours. At steady-state, the rate of drug administration equals the rate of
elimination.
, Page |2
3. The CYP450 enzyme system is primarily located in which organ and is
responsible for:
A) The liver; Phase I metabolism (oxidation, reduction, hydrolysis)
B) The kidneys; filtration
C) The lungs; gas exchange
D) The intestines; absorption
Answer: A
Rationale: The Cytochrome P450 (CYP) enzyme system is predominantly located in
the liver's endoplasmic reticulum. It catalyzes Phase I reactions, which introduce a
reactive functional group onto the drug molecule.
4. A patient on warfarin is started on a drug that strongly inhibits CYP2C9. What
is the expected clinical outcome?
A) Warfarin will be metabolized faster, leading to reduced anticoagulation.
B) Warfarin will be metabolized slower, leading to increased INR and bleeding risk.
C) No change in warfarin levels.
D) Warfarin will be excreted faster.
Answer: B
Rationale: Warfarin is metabolized by CYP2C9. If this enzyme is inhibited, warfarin
metabolism decreases, leading to higher plasma concentrations. This increases the
patient's INR and significantly raises the risk of major bleeding.
5. A drug has a volume of distribution (Vd) of 10,000 L. This indicates that the
drug is:
A) Highly bound to plasma proteins
B) Highly tissue-bound and widely distributed into extravascular tissues
C) Primarily confined to the vascular space
D) Excreted rapidly
Answer: B
Rationale: Volume of distribution (Vd) is a theoretical volume that relates the
amount of drug in the body to the plasma concentration. A very high Vd (like
, Page |3
10,000 L) indicates that the drug is extensively distributed into tissues (e.g., fat,
muscle, organs).
6. The "first-pass effect" refers to:
A) The metabolism of a drug in the liver before it reaches systemic circulation,
which significantly reduces the bioavailability of oral medications
B) The first dose of a drug given to a patient
C) The absorption of a drug in the stomach
D) The excretion of a drug in the urine
Answer: A
Rationale: The first-pass effect occurs when an orally administered drug is
absorbed from the GI tract and passes through the portal vein into the liver before
it can enter the systemic circulation. The liver may metabolize a significant portion
of the drug.
Domain 2: Autonomic Nervous System Pharmacology (Adrenergic & Cholinergic)
7. Which neurotransmitter is released at the postganglionic terminals of the
parasympathetic nervous system?
A) Norepinephrine
B) Dopamine
C) Acetylcholine
D) Epinephrine
Answer: C
Rationale: In the parasympathetic nervous system, both the preganglionic and
postganglionic neurons release acetylcholine (ACh).
8. A patient is given a drug that stimulates the sympathetic nervous system
(sympathomimetic). Which receptor type is primarily responsible for causing
bronchodilation?
A) Alpha-1 (α₁)
B) Alpha-2 (α₂)
